Global Pharyngitis Tablets Market Overview:
Pharyngitis is refer as the medical condition which causes the inflammation at the back of the throat refer as pharynx or sour throat. Pharyngitis sometimes also leads to difficulty and itchiness in swallowing. There are some of the viral and bacterial agents which causes pharyngitis, majority of it includes measles, croup, whooping cough, adenovirus, chickenpox, and group A streptococcus. Pharyngitis is basically caused by viral infection such as common cold, mononucleosis, and influenza. The most common bacterial infection is strep throat which is caused by group A streptococcus. The other common symptoms of pharyngitis includes sneezing, fatigue, body aches, runny nose, headache, cough, chills, and fever. Pharyngitis tablets are used for the treatment of sour throat that is pharyngitis.
- Increase in the prevalence of pharyngitis globally
- Developing healthcare infrastructure and high disposable income
- High investment of the Government for the Research & Development (R&D) of novel therapies and drugs to treat pharyngitis
- The immense pace of R&D activities due to the presence of large biotechnology and pharmaceutical companies
- Recent expiries of patented drugs, generic drugs that are available for the treatment are anticipated to hamper the growth of the market
- Technological advancement in the diagnosis of pharyngitis leading to patented drugs for treatment is providing an opportunity for the market
- Cost factor associated with the treatment of pharyngitis is posing a challenge for the market
The market appears to be fragmented due to a large number of players in the market who are heavily investing in R&D for the development of novel therapies and drugs to treat pharyngitis. Moreover, regulatory bodies of the healthcare sector are paying more attention on novel drugs by giving faster approvals and special status for the drugs.
Some of the key players profiled in the report are GSK group of companies (United Kingdom), Pfizer Inc. (United States), Genentech Inc. (United States), McNeil (United States), Adamas Pharmaceutical Inc. (United States), PLIVA HRVATSKA d.o.o. (Croatia), Valeant Pharmaceuticals International, Inc. (Canada), Mylan N.V. (United States), Teva Pharmaceutical Industries Ltd. (Israel) and AbbVie Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Pharyngitis Tablets market by 2026. Considering Market by Distribution Channel, the sub-segment i.e. Hospitals will boost the Pharyngitis Tablets market. Considering Market by Source, the sub-segment i.e. Viral will boost the Pharyngitis Tablets market. Considering Market by Symptoms, the sub-segment i.e. Sore Throat will boost the Pharyngitis Tablets market.
According to the American Osteopathic Association (AOA), pharyngitis induced sore throat in one of the leading reasons for physician visits in the United States. Viral infection such as common cold, influenza, and mononucleosis are some of the most common causes of sore throat. According to the World Health Organization, around 3-5 million cases of severe flu are recorded every year worldwide and between 2, 50,000 to 3, 00,000 deaths occur.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Pharyngitis Tablets market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Pharyngitis Tablets market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceutical Companies, Healthcare Industry, Government and Regulatory Bodies and Distributor, Suppliers, Traders of Pharyngitis Tablet Manufacturers.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.